Alternative splicing is generally regulated by trans-acting factors that specifically bind pre-mrnA to activate or inhibit the splicing reaction. this regulation is critical for normal gene expression, and dysregulation of splicing is closely associated with human diseases. here we engineered artificial splicing factors by combining sequence-specific rnA-binding domains of human Pumilio1 with functional domains that regulate splicing. We applied these factors to modulate different types of alternative splicing in selected targets, to examine the activity of effector domains from natural splicing factors and to modulate splicing of an endogenous human gene, Bcl-X, an anticancer target. the designer factor targeted to Bcl-X increased the amount of pro-apoptotic Bcl-xs splice isoform, thus promoting apoptosis and increasing chemosensitivity of cancer cells to common antitumor drugs. our approach permitted the creation of artificial factors to target virtually any pre-mrnA, providing a strategy to study splicing regulation and to manipulate disease-associated splicing events.
Alternative splicing is generally regulated by trans-acting factors that specifically bind pre-mrnA to activate or inhibit the splicing reaction. this regulation is critical for normal gene expression, and dysregulation of splicing is closely associated with human diseases. here we engineered artificial splicing factors by combining sequence-specific rnA-binding domains of human Pumilio1 with functional domains that regulate splicing. We applied these factors to modulate different types of alternative splicing in selected targets, to examine the activity of effector domains from natural splicing factors and to modulate splicing of an endogenous human gene, Bcl-X, an anticancer target. the designer factor targeted to Bcl-X increased the amount of pro-apoptotic Bcl-xs splice isoform, thus promoting apoptosis and increasing chemosensitivity of cancer cells to common antitumor drugs. our approach permitted the creation of artificial factors to target virtually any pre-mrnA, providing a strategy to study splicing regulation and to manipulate disease-associated splicing events.
As a key regulatory step in gene expression, alternative splicing is widespread in humans with most genes producing multiple splicing isoforms with distinct and sometimes opposing functions 1 . The choice of splicing isoforms is tightly regulated in different tissues and developmental processes, and disruption of such regulation is a common cause of human disease 2 . Therefore new approaches to specifically modulate alternative splicing will improve our understanding of splicing regulation and will have therapeutic potential.
Generally, the splicing process is regulated through cis-acting elements that recruit trans-acting splicing factors to affect use of nearby splice sites. Many splicing factors have modular organization, with separate sequence-specific RNA binding modules and splicing effector domains. For example, serine/arginine-rich proteins contain N-terminal RNA recognition motifs (RRMs) that bind to exonic splicing enhancers in pre-mRNAs and C-terminal arginine/serine-rich domains that promote exon inclusion 3 . Analogously, the heterogeneous nuclear ribonucleoprotein (hnRNP) A1 binds to exonic splicing silencers through its RRM and inhibits exon inclusion through a C-terminal glycine-rich domain 4 . Following this configuration, we envisioned engineering splicing factors with designed specificities Yang Wang 1 , Cheom-Gil Cheong 2 , Traci M Tanaka Hall 2 & Zefeng Wang 1 engineering unique factors by combining an RNA recognition module to recognize targets with a functional module to affect splicing. Ideally, such an engineered splicing factor (ESF) should recognize any target and modulate splicing in desired ways.
Here we report what, to our knowledge, is the first attempt to engineer splicing factors with designed sequence specificity and activities. These ESFs can promote or suppress splicing and can specifically recognize target genes undergoing different types of alternative splicing. We used such ESFs to study the functional domains of natural splicing factors and designed a new ESF to specifically modulate splicing of an endogenous gene. The 'designer' ESF can shift splicing of Bcl-X (BCL2L1) to increase the pro-apoptotic isoform in multiple cultured cancer cells, therefore sensitizing these cells to common antitumor drugs.
results design principles of esFs
To generate an RNA-binding module with predictable specificity, we used the unique RNA recognition mode of PUF proteins (named for Drosophila melanogaster Pumilio and Caenorhabditis elegans fem-3 binding factor) that are involved in mediating mRNA stability and translation 5 . Most splicing factors recognize their targets through RRMs or K homology domains that bind to short RNA elements with moderate affinities. However, it is impractical to engineer an RNA recognition module using these domains because of their weak binding affinity and the absence of a predictive RNA recognition code. The PUF domain of human Pumilio1 binds tightly to cognate RNA sequences, and its specificity can be modified. It contains eight PUF repeats that recognize eight consecutive RNA bases with each repeat recognizing a single base 6 (Fig. 1a) . Two amino acid side chains in each repeat recognize the Watson-Crick edge of the corresponding base and determine the specificity of that repeat, thus a PUF domain can be designed to specifically bind most 8-nucleotide RNAs 6, 7 . To generate a sequence-specific ESF, we fused a modified PUF domain with a splicing regulatory domain: an arginine/serine-rich domain for a splicing activator or a glycine-rich domain for a splicing repressor. We also included a nuclear localization sequence to direct the ESF to the nucleus where splicing occurs and a Flag tag to facilitate detection (Fig. 1b) .
specifically modulating exon inclusion with esFs
To test the design concept, we created six ESFs by fusing either the glycine-rich (Gly) domain of hnRNP A1 or the arginine/ serine-rich (RS) domain of ASF, also known as SF2 (ASF/SF2) with three different PUF domains (wild-type human Pumilio1 and two modified PUF domains) to obtain Gly-PUF-type or RS-PUF-type ESFs. Wild-type PUF specifically binds to Nanos response element RNA sequence, whereas the PUF(3-2) mutant (C935S,Q939E; PUF(3-2) indicates two mutated amino acid in PUF repeat 3) recognizes A6G sequence and the PUF(6-2/7-2) mutant (N1043S,Q1047E mutations in PUF repeat 6 and S1079N,E1083Q mutations in repeat 7) recognizes GU/UG sequence 6, 7 (Fig. 1c) . We generated exon-skipping reporters containing the corresponding 8-nucleotide target sequences of the ESFs in the alternatively spliced cassette exon. We transfected these reporters into 293T cells with the ESF expression constructs and analyzed changes in splicing using reverse transcriptase (RT)-PCR.
Consistent with our prediction, the Gly-PUF-type ESFs repressed inclusion of the cassette exon containing a cognate target sequence (Fig. 1d-f) . Such inhibition was sequence-specific, with the maximal inhibition of exon inclusion occurring between cognate ESFs and reporters (Fig. 1e) . The splicing repressor activities of Gly-PUF-type ESFs correlated roughly with the binding affinities of PUF motifs to their targets (Supplementary Fig. 1 ), suggesting that the binding affinity to its target contributes to splicing factor strength.
In line with the above observations, RS-PUF-type ESFs had opposite activity on splicing and promoted inclusion of cassette exons containing cognate targets (Fig. 1g-i) . The activities of these ESFs correlated roughly with the binding affinities of PUF motifs to their targets (Supplementary Fig. 1 ), supporting the modular configuration of splicing factors 8, 9 . In addition, both types of ESFs were effective in the different cell types tested, suggesting that their activities were not cell linespecific (Supplementary Fig. 2) .
Despite a clear trend, the correlation between ESF activities and their binding affinities to targets was not completely linear ( Supplementary Fig. 1 ), as we observed considerable exon skipping or, less prominently, inclusion, between some noncognate pairs of ESFs and targets ( Fig. 1d : Nanos response element and A6G sequences). This nonlinearity is likely due to a combination of sequence-specific and nonspecific effects of splicing factors. We used a 1:5 ratio of Gly-PUF expression plasmid to splicing reporter plasmid, which represents the lower end of the range that gave robust activity and is substantially lower than the ratios typically used in splicing factor/splicing reporter transfection experiments 10 . We optimized this ratio by titrating the amount of the ESF expression plasmid to a fixed amount (0.2 µg in 1 ml cell culture) of splicing reporter plasmid (Supplementary Fig. 3 ). Higher amounts of splicing factor expression vector caused exon skipping for all reporters, including those with pseudospecific target sequences (Supplementary Fig. 3 ). We had previously observed similar effects of hnRNP A1 and ASF/SF2 in tethering experiments with MS2 coat protein 11 . Therefore, as for other processes involving protein-RNA binding, the sequence specificity of splicing factors can only be considered in the context of certain concentration ranges.
esFs specifically modulate use of alternative splice sites In addition to regulating exon skipping or inclusion, some splicing factors regulate alternative use of splice sites by recognizing regulatory sequences between two alternative sites. ASF/SF2 can recognize exonic splicing enhancers and promote the use of intron-proximal sites, whereas hnRNP A1 can bind exonic splicing silencers and shift splicing toward the use of intron-distal sites [12] [13] [14] . Therefore we next examined whether ESFs can predictably regulate alternative 5′ or 3′ splice site usage with ESFs containing the same PUF domains (Fig. 1c) . We designed reporters containing cognate target sequences between tandem 5′ splice sites 11 and transfected them with the RS-PUF-type ESFs. As expected, RS-PUFs increased the use of the downstream intron-proximal 5′ splice sites, with the strongest effect on reporters bearing their cognate sequence (Fig. 2a,b) . Similarly, the RS-PUFs modulated alternative 3′ splice site usage (by promoting the use of upstream 3′ splice sites) in a sequence-specific fashion (Fig. 2c,d ), indicating that these ESFs can modulate different alternative splicing events. Owing to the combination of sequence-specific and nonspecific effects, we also found that ESFs can affect splicing of pseudospecific targets in an alternative 3′ splice site reporter.
examining various functional domains in esFs
Compared to conventional tethering experiments using the MS2 coat protein or lambda N-B box systems 15 , ESFs, which specifically recruit different proteins or domains to certain pre-mRNA regions, can recognize the pre-mRNA in a natural context without introducing foreign RNA and thus are more advantageous for in vivo applications. Previous studies using in vitro splicing systems had shown that arginine/serine-rich domains from various proteins (or even a short peptide of arginine/serine-rich repeats) can function as splicing activators 3, 16 . To test whether other arginineserine-rich domains can function as the effector module of ESFs, we generated new ESFs by fusing a PUF domain (PUF(3-2)) with arginine/serine-rich domains from other serine/arginine-rich proteins (9G8, SC35 and SRp40) or a short peptide of arginine/serinerich repeats (six repeats of RS dipeptides (RS) 6 ), and examined whether these new ESFs promote exon inclusion when transfected with their target-containing splicing reporters (Fig. 3a) . Compared to the non-ESF control, all RS-PUFs promoted inclusion of the cassette exon containing their cognate sequences (Fig. 3b) . The short arginine/serine-rich repeat had similar activity to the other arginine/serine-rich domains, with the exception of the arginine/ serine-rich domain from 9G8, which has slightly higher activity than the rest of the arginine/serine-rich domains (Fig. 3c) .
Glycine-rich domains are also found in many known splicing factors, especially members of hnRNP A1 family. However, it is unclear whether these glycine-rich domains can function as general splicing inhibitors, as only the domain from hnRNP A1 represses splicing when tethered to the exonic region 4 . To test whether glycine-rich domains have intrinsic splicing inhibitory activity, we generated new ESFs by fusing PUF(3-2) with the glycine-rich domains from additional hnRNP A1 family members (hnRNP A2/B1 and hnRNP A3) or with a glycine-rich short peptide (19 amino acids) and examined whether they can inhibit exon inclusion when transfected along with a splicing reporter (Fig. 3a) . We found that all Gly-PUF constructs suppressed the inclusion of the cassette exon containing their cognate sequence (Fig. 3b) , indicating that the glycine-rich domains in members of hnRNP A1 family are likely responsible for their splicing suppression activity. Notably, a 19-amino-acid glycine-rich sequence was sufficient for splicing-inhibitory activity (Fig. 3b-c) , suggesting that other splicing factors with a glycine-rich domain may function as splicing suppressors when binding to exons. PUF domains alone did not affect splicing of the same reporters ( Supplementary Fig. 4) , suggesting that glycine-rich domains are responsible for splicing inhibition. We used the well-studied glycine-rich domain from hnRNP A1 for the subsequent experiments.
designing an esF to modulate endogenous gene splicing An important application for ESFs is to modulate alternative splicing of endogenous genes, particularly disease-associated splicing events. To demonstrate this, we chose to target the Bcl-X pre-mRNA that produces two splicing isoforms of opposite function using alternative 5′ splice sites 17 (Fig. 4a) . The long splicing isoform bcl-xL encodes a potent apoptosis inhibitor in longlived postmitotic cells and is upregulated in many cancer cells to protect them against apoptotic signals. The short splice isoform Bcl-xS is pro-apoptotic and is expressed predominantly in cells with a high turnover rate (for example, developing lymphocytes) 18 .
Others have used antisense oligonucleotide-based methods to inhibit the use of the intron proximal 5′ splice site and increase pro-apoptotic Bcl-xS [19] [20] [21] [22] .
The ratio of the two Bcl-x splicing isoforms is regulated by multiple cis-acting elements that are located near the two alternative 5′ splice sites 23 . To shift the splicing of Bcl-X, we designed a Gly-PUF-type ESF to recognize the 8-nucleotide sequence in the exon extension region, a sequence that otherwise does not affect splicing (data not shown). This designer ESF should be able to 'reprogram' the splicing regulation of Bcl-X to increase Bcl-xS isoform, which in turn can promote apoptosis (Fig. 4a) . We mutated the first, third and fifth repeats of the wild-type PUF domain and verified that this modified domain (Q867E,Q939E,C935S,Q1011E, C1007S, named PUF(531)) can recognize its new target with very high affinity (K d ≈ 4 pM; Supplementary Fig. 5 ) compared to the wild-type PUF affinity for this sequence (K d = 660 ± 17 nM). When we transfected the expression plasmid into HeLa cells in which Bcl-xL was the predominant form, Gly-PUF(531) increased splicing of the Bcl-xS isoform in a dose-dependent manner, whereas the control ESF (Gly-PUF(WT)) or PUF(531) alone did not affect the bcl-xS mRNA level ( Fig. 4b and Supplementary Fig. 4b ).
We also observed the increase in the amount of Bcl-xS using western blots (Fig. 4c) , suggesting that the change of steadystate Bcl-xS/Bcl-xL ratio is probably due to a splicing shift rather than destabilization of bcl-xL mRNA by PUF(531) binding. The amounts of Bcl-xL were not notably different under our experimental conditions, probably owing to a higher sensitivity of the Bcl-x antibody in detecting Bcl-xL than Bcl-xS 19, 20 ( Supplementary Fig. 6 ).
designer esF induced apoptosis
Induction of the pro-apoptotic Bcl-xS isoform by Gly-PUF(531) led to cleavage of caspase 3 and poly(ADP-ribose) polymerase (PARP), two known molecular markers in the apoptosis pathway (Fig. 4d) . Using immunofluorescence microscopy, we observed that many cells expressing Gly-PUF(531) had fragmented nuclear DNA, indicating that they were undergoing apoptosis (Fig. 4e) . Examination of >200 cells from randomly chosen fields in two independent experiments indicated that ~10% of cells transfected with Gly-PUF(531) expression plasmid had fragmented nuclear DNA versus only ~3% in control cells (Fig. 4f) . We also noted that, as designed, the ESFs were localized predominantly in the nuclei of transfected cells (Fig. 4e) , suggesting ESFs dissociate from their targets when the fully spliced mRNAs are transported into the cytoplasm. In addition to HeLa cells, we tested Gly-PUF(531) in other cells including a breast cancer cell line (MDA-MB-231) and a lung cancer cell line (A549). We infected the cells with lentivirus expressing Gly-PUF(531) or control ESF and found that the designer ESF caused a considerable shift of splicing to produce more Bcl-xS isoform in all cell types tested (Fig. 5a) . For reasons that are not completely clear, the lentivirus-infected Hela cells had an elevated basal amount of Bcl-xS. Such a splicing shift increased apoptosis as determined by flow cytometry of propidium iodide-stained cells (Fig. 5a) . In the absence of an exogenous stimulus that induces apoptosis, the increases of apoptotic cells were modest (about threefold) but significant in all cell types tested (P < 0.05, paired t-test), consistent with Bcl-xL being an important apoptosis inhibitor for most cancers 18 .
designer esF sensitized cancer cells to antitumor drugs
As the increase of Bcl-xS released inhibition of apoptosis, we expected a more apparent effect on cell survival during induction of apoptosis by chemotherapeutic drugs. We treated the different cancer cells with either Gly-PUF(531) or control Gly-PUF(WT) in combination with antitumor drugs (cisplatin and paclitaxel) or cytokines (TNF-α and TNF-related apoptosis inducing ligand (TRAIL)), which are commonly used in cancer treatments. To achieve robust expression during the entire period of drug treatment, we infected the MDA-MB-231, A549 and HeLa cells with lentivirus expressing Gly-PUF(531) or control ESF and then treated the infected cells with low doses of drugs for 24 h, conditions under which most mock-infected cancer cells were viable (Fig. 5b-e) .
In all cell types tested, expression of Gly-PUF(531) sensitized cells to the antitumor drugs tested, leading to significant decreases of cell viability compared to controls (P < 0.05) as judged by WST-1 cell proliferation assay. Different cell lines responded to the combinations of antitumor drugs and ESFs with varying sensitivities (Figs. 5b-e) , consistent with the diverse mechanisms by which these drugs kill cancer cells. The enhancements of drug sensitivity in ESF-treated cancer cells were in the same range as cells treated with small-molecule inhibitors of Bcl-xL 24, 25 . discussion A design similar to the one presented here could be adopted to study other RNA processing steps (for example, polyadenylation or RNA degradation) that are regulated through interactions between RNA cis-elements and protein trans-acting factors. The development of ESFs also provides a strategy to manipulate disease-associated splicing events, potentially leading to new treatment for diseases associated with aberrant splicing. Previous methods to modulate disease-related splicing have used antisense oligonucleotides to mask the splicing signals 26 or to recruit additional factors through an extended unpaired tail 27, 28 , which require relatively high doses of oligonucleotides to effectively change splicing. The design of ESFs uses a fundamentally different strategy: to directly recognize targets through protein-RNA interaction and thus to reprogram the splicing regulation code. Compared to antisense methods, ESFs are more flexible because they can positively or negatively affect multiple types of alternative splicing. By optimizing various combinations of ESF modules, this approach will allow fine-tuned adjustment of alternative splicing. In addition, ESFs could be stably expressed in vivo using the current arsenal of gene therapy and expression tools, whereas the delivery and in vivo stability of antisense oligonucleotides are still difficult to control. Finally, in addition to manipulating disease-associated splicing, this new approach has immediate impact as a new system to study factors that regulate splicing or other RNA processing pathways.
The RNA-binding module of our ESFs, the PUF domain, allows target-discriminatory power similar to that of microRNAs, which recognize targets mainly by a 7-nucleotide seed match. Improving ESF specificity will minimize off-target effects, which may be achieved by recognizing longer target sequences using two tandem PUFs or creating a PUF with more repeats. A possible concern with the PUF domain is that repeats can be designed to recognize adenine, guanine or uracil, but amino acid residues that specify recognition of cytosine have not been determined. This might present a limitation if a target sequence must be chosen in a small region. However, a cytosine can be tolerated at position 5 in the target sequence, providing us with the ability to target a sequence with one cytosine. Future work to determine the recognition code for a cytosine by a PUF repeat could address this issue.
In addition to manipulating disease-associated splicing events, ESFs may be designed to create animal models of splicing diseases or to examine the physiological effects of particular alternative splicing choices. Another important application of ESFs is to study the self-regulation of splicing factors. Many splicing factors regulate their own splicing through a feedback loop 29, 30 , but it is difficult to dissect such a regulatory network because these factors usually also regulate the splicing of essential genes for cell survival. Designing ESFs to direct the splicing of their own premRNAs provides a unique opportunity to construct new splicing regulatory feedback loops or even new regulatory networks, thus could be used to systematically model how splicing regulation is achieved. online methods ESF expression constructs. To express ESFs in cultured cells, we generated expression constructs using the pCI-neo vector (Promega). We started with an expression plasmid that encodes (from N to C terminus) a Flag epitope, glycine-rich domain of hnRNP A1 (residues 195-320, RefSeq identifier: NP_002127), and the MS2 coat protein plasmids (gift of R. Breathnach; Institut de Biologie-CHR 31 ). The fragment encoding the MS2 coat protein was removed using BamHI and SalI digestion and replaced with a fragment encoding a nuclear localization sequence (PPKKKRKV) and the PUF domain of human Pumilio1, which was amplified using primers Pum-F1 and Pum-R1 (Supplementary Table 1) . The resulting construct expresses a Gly-PUF-type ESF under the control of a CMV promoter (Fig. 1b) . To make an expression construct for an RS-PUF-type ESF, we removed the fragment encoding the Flag-tagged glycine-rich domain with NheI and BamHI digestion, and replaced it with a fragment that encodes the arginine-serine-rich (RS) domain of ASF/SF2 protein with an N-terminal Flag epitope, which was amplified using primers ASF-RS-F and ASF-RS-R (Supplementary Table 1 ). To generate constructs for different ESFs with mutated PUF domains, we introduced the point mutations in consecutive steps using a QuikChange Site-Directed Mutagenesis kit (Stratagene) following manufacturer's instructions 32 . To modulate Bcl-X splicing, the sequence UGUGCGUG between the two 5′ splice sites was chosen as ESF target, and mutations were introduced in PUF repeats 1, 3 and 5 (Q867E,Q939E,C935S,Q1011E,C1007S) to recognize this sequence. The additional functional domains of ESF (RS domains/fragment or glycine-rich domains/fragment) were amplified by PCR (or synthesized oligonucleotides for short fragments), and cloned between XhoI and BamHI. The RS domains are residues 123-238 of 9G8 (NP001026854), residues 180-272 of SRp40 (NP008856), residues 117-221 of SC35 (NP003007) and an (RS) 6 sequence. The glycine-rich domains are residues 203-353 of hnRNP A2 (RefSeq identifier: NP112533), residues 211-378 of hnRNP A3 (RefSeq ID: NP919223) and the peptide GYGGGGPGYGNQGGGYGGG.
Splicing reporter constructs.
To assess the effects of ESFs on exon skipping, we used a modular reporter system that allowed us to change an inserted splicing regulatory sequence near a test exon (exon 12 of the human IGF-II mRNA-binding protein 1, IGF2BP1, Ensembl ID ENSG00000159217) and assay for the inclusion of this test exon. The test exon, together with its flanking introns, was inserted between two GFP exons in pEGFP-C1 vectors as described previously 33 . To insert target sequences of PUF domains into this reporter vector, we synthesized and annealed oligonucleotides containing the candidate sequences (designated by N8) flanked by XhoI and ApaI sites. The resulting DNA fragments were digested and ligated into the XhoI and ApaI digested vector (inside the test exon). The inclusion of the test exon is assayed by body-labeled RT-PCR, as described previously 34 , with primers corresponding to the first and third exon (two GFP exons) of the reporter minigene 4 .
To assess the effect of ESFs on the alternative use of 5′ and 3′ splice sites, we used reporters with competing 5′ and 3′ splice sites 34 . The same target sequences of PUF domains were inserted into these reporters using either XhoI and ApaI sites (for the competing 3′ splice site reporter) or XhoI and EcoRI sites (for the
